[1rarebird]

I posted this question at BC.org but haven't yet received any feed back. Maybe my luck will be better here.

I believe I read somewhere that Neratinib possibly may help prevent "cross talk signaling" between the Her1 and Her2 receptors, or the Her1 or 2 receptors and ERs. If this is true, could it be part of why Her2+ cancers can sometimes exhibit resistance to trastuzumab (Herceptin), and would Neratinib or even Laptinib help prevent such cross talk between (among) the receptors?

I don't know if this trial's investigators are looking at this question too. This is complicated stuff for me to understand, but if the anti-cross-talk question is valid, it may give another reason to sign up for the trial.

Thanks

bird

Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH, radiation, Tamoxifen therapy planned